These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
217 related articles for article (PubMed ID: 21196371)
1. Angiogenic and lymphangiogenic cascades in the tumor microenvironment. Onimaru M; Yonemitsu Y Front Biosci (Schol Ed); 2011 Jan; 3(1):216-25. PubMed ID: 21196371 [TBL] [Abstract][Full Text] [Related]
2. Collaborative interplay between FGF-2 and VEGF-C promotes lymphangiogenesis and metastasis. Cao R; Ji H; Feng N; Zhang Y; Yang X; Andersson P; Sun Y; Tritsaris K; Hansen AJ; Dissing S; Cao Y Proc Natl Acad Sci U S A; 2012 Sep; 109(39):15894-9. PubMed ID: 22967508 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of lymphangiogenesis and angiogenesis in breast tumor xenografts and lymph nodes by a peptide derived from transmembrane protein 45A. Lee E; Koskimaki JE; Pandey NB; Popel AS Neoplasia; 2013 Feb; 15(2):112-24. PubMed ID: 23441126 [TBL] [Abstract][Full Text] [Related]
4. Molecular control of lymphatic metastasis. Achen MG; Stacker SA Ann N Y Acad Sci; 2008; 1131():225-34. PubMed ID: 18519975 [TBL] [Abstract][Full Text] [Related]
5. Differential Receptor Binding and Regulatory Mechanisms for the Lymphangiogenic Growth Factors Vascular Endothelial Growth Factor (VEGF)-C and -D. Davydova N; Harris NC; Roufail S; Paquet-Fifield S; Ishaq M; Streltsov VA; Williams SP; Karnezis T; Stacker SA; Achen MG J Biol Chem; 2016 Dec; 291(53):27265-27278. PubMed ID: 27852824 [TBL] [Abstract][Full Text] [Related]
6. The tyrosine kinase inhibitor cediranib blocks ligand-induced vascular endothelial growth factor receptor-3 activity and lymphangiogenesis. Heckman CA; Holopainen T; Wirzenius M; Keskitalo S; Jeltsch M; Ylä-Herttuala S; Wedge SR; Jürgensmeier JM; Alitalo K Cancer Res; 2008 Jun; 68(12):4754-62. PubMed ID: 18559522 [TBL] [Abstract][Full Text] [Related]
7. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3. Kodera Y; Katanasaka Y; Kitamura Y; Tsuda H; Nishio K; Tamura T; Koizumi F Breast Cancer Res; 2011 Jun; 13(3):R66. PubMed ID: 21693010 [TBL] [Abstract][Full Text] [Related]
9. Differential expression of VEGF ligands and receptors in prostate cancer. Woollard DJ; Opeskin K; Coso S; Wu D; Baldwin ME; Williams ED Prostate; 2013 May; 73(6):563-72. PubMed ID: 23038639 [TBL] [Abstract][Full Text] [Related]
10. VEGF-C and VEGF-C156S in the pro-lymphangiogenic growth factor therapy of lymphedema: a large animal study. Visuri MT; Honkonen KM; Hartiala P; Tervala TV; Halonen PJ; Junkkari H; Knuutinen N; Ylä-Herttuala S; Alitalo KK; Saarikko AM Angiogenesis; 2015 Jul; 18(3):313-26. PubMed ID: 26018927 [TBL] [Abstract][Full Text] [Related]
11. Tumor lymphangiogenesis and lymphangiogenic growth factors. Da MX; Wu Z; Tian HW Arch Med Res; 2008 May; 39(4):365-72. PubMed ID: 18375246 [TBL] [Abstract][Full Text] [Related]
12. Blocking Fibroblast Growth Factor receptor signaling inhibits tumor growth, lymphangiogenesis, and metastasis. Larrieu-Lahargue F; Welm AL; Bouchecareilh M; Alitalo K; Li DY; Bikfalvi A; Auguste P PLoS One; 2012; 7(6):e39540. PubMed ID: 22761819 [TBL] [Abstract][Full Text] [Related]
13. Anti-VEGF-A therapy reduces lymphatic vessel density and expression of VEGFR-3 in an orthotopic breast tumor model. Whitehurst B; Flister MJ; Bagaitkar J; Volk L; Bivens CM; Pickett B; Castro-Rivera E; Brekken RA; Gerard RD; Ran S Int J Cancer; 2007 Nov; 121(10):2181-91. PubMed ID: 17597103 [TBL] [Abstract][Full Text] [Related]
14. Vascular endothelial growth factor C stimulates progression of human gastric cancer via both autocrine and paracrine mechanisms. Kodama M; Kitadai Y; Tanaka M; Kuwai T; Tanaka S; Oue N; Yasui W; Chayama K Clin Cancer Res; 2008 Nov; 14(22):7205-14. PubMed ID: 19010837 [TBL] [Abstract][Full Text] [Related]
15. Foretinib inhibits angiogenesis, lymphangiogenesis and tumor growth of pancreatic cancer in vivo by decreasing VEGFR-2/3 and TIE-2 signaling. Chen HM; Tsai CH; Hung WC Oncotarget; 2015 Jun; 6(17):14940-52. PubMed ID: 25909285 [TBL] [Abstract][Full Text] [Related]
16. Transgenic induction of vascular endothelial growth factor-C is strongly angiogenic in mouse embryos but leads to persistent lymphatic hyperplasia in adult tissues. Lohela M; Heloterä H; Haiko P; Dumont DJ; Alitalo K Am J Pathol; 2008 Dec; 173(6):1891-901. PubMed ID: 18988807 [TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor c promotes ovarian carcinoma progression through paracrine and autocrine mechanisms. Decio A; Taraboletti G; Patton V; Alzani R; Perego P; Fruscio R; Jürgensmeier JM; Giavazzi R; Belotti D Am J Pathol; 2014 Apr; 184(4):1050-1061. PubMed ID: 24508126 [TBL] [Abstract][Full Text] [Related]
18. Perspectives on lymphangiogenesis and angiogenesis in cancer. Holopainen T; Bry M; Alitalo K; Saaristo A J Surg Oncol; 2011 May; 103(6):484-8. PubMed ID: 21480240 [TBL] [Abstract][Full Text] [Related]
19. Tumor-derived interleukin-1 promotes lymphangiogenesis and lymph node metastasis through M2-type macrophages. Watari K; Shibata T; Kawahara A; Sata K; Nabeshima H; Shinoda A; Abe H; Azuma K; Murakami Y; Izumi H; Takahashi T; Kage M; Kuwano M; Ono M PLoS One; 2014; 9(6):e99568. PubMed ID: 24924428 [TBL] [Abstract][Full Text] [Related]
20. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth. Gacche RN; Meshram RJ Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]